Coccidioidomycosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major coccidioidomycosis markets reached a value of US$ 132.9 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 209.5 Million by 2034, exhibiting a growth rate (CAGR) of 4.22% during 2024-2034.
The coccidioidomycosis market has been comprehensively analyzed in IMARC's new report titled "Coccidioidomycosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Coccidioidomycosis, also known as valley fever, refers to a fungal infection that arises due to the inhalation of spores from the fungi Coccidioides posadasii or Coccidioides immitis. The indications of this condition can vary widely, ranging from mild flu-like symptoms to serious and potentially life-threatening complications. The ailment usually manifests as fever, cough, fatigue, headache, and muscle aches. In some cases, the disorder can progress to a more severe form, leading to pneumonia, skin rashes, joint pain, and, rarely, dissemination to several other organs, like the brain and bones. The diagnosis of coccidioidomycosis typically involves a combination of clinical evaluation, imaging studies, physical examination, and laboratory tests. The healthcare provider may also conduct blood workups to detect antibodies against the fungi or use imaging techniques, such as CT scans or chest X-rays, to identify characteristic lung lesions. In severe cases or when dissemination is suspected, a biopsy may be necessary for confirmation.
The rising prevalence of inhaling airborne fungal spores due to disturbances in the soil caused by factors like dust storms and construction activities is primarily driving the coccidioidomycosis market. In addition to this, the escalating incidence of somatic mutations in the GNAQ gene, leading to overgrowth of the fungus in certain regions of the body, particularly the respiratory system, is a crucial factor fueling the market growth. Furthermore, the increasing utilization of effective antifungal medications, such as azoles, polyenes, echinocandins, etc., to manage the condition and prevent complications is creating a positive outlook for the market. Apart from this, the widespread adoption of preventive measures, including wearing masks and avoiding high-risk areas, has also contributed to the market's expansion. Additionally, the rising popularity of early diagnosis through serological tests and chest X-rays, enabling prompt treatment and reducing disease progression, is acting as another significant growth-inducing factor. Moreover, the emerging trend of adopting combination therapy, involving a few different types of antifungal agents in severe cases, is further augmenting the market growth. Additionally, the growing research and development efforts towards launching a therapeutic vaccine aimed at providing long-term immunity and prevention against the disease are expected to drive the coccidioidomycosis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the coccidioidomycosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for coccidioidomycosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the coccidioidomycosis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the coccidioidomycosis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the coccidioidomycosis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current coccidioidomycosis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the coccidioidomycosis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the coccidioidomycosis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the coccidioidomycosis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of coccidioidomycosis across the seven major markets?
What is the number of prevalent cases (2018-2034) of coccidioidomycosis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of coccidioidomycosis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with coccidioidomycosis across the seven major markets?
What is the size of the coccidioidomycosis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of coccidioidomycosis?
What will be the growth rate of patients across the seven major markets?
Coccidioidomycosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for coccidioidomycosis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the coccidioidomycosis market?
What are the key regulatory events related to the coccidioidomycosis market?
What is the structure of clinical trial landscape by status related to the coccidioidomycosis market?
What is the structure of clinical trial landscape by phase related to the coccidioidomycosis market?
What is the structure of clinical trial landscape by route of administration related to the coccidioidomycosis market?
The coccidioidomycosis market has been comprehensively analyzed in IMARC's new report titled "Coccidioidomycosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Coccidioidomycosis, also known as valley fever, refers to a fungal infection that arises due to the inhalation of spores from the fungi Coccidioides posadasii or Coccidioides immitis. The indications of this condition can vary widely, ranging from mild flu-like symptoms to serious and potentially life-threatening complications. The ailment usually manifests as fever, cough, fatigue, headache, and muscle aches. In some cases, the disorder can progress to a more severe form, leading to pneumonia, skin rashes, joint pain, and, rarely, dissemination to several other organs, like the brain and bones. The diagnosis of coccidioidomycosis typically involves a combination of clinical evaluation, imaging studies, physical examination, and laboratory tests. The healthcare provider may also conduct blood workups to detect antibodies against the fungi or use imaging techniques, such as CT scans or chest X-rays, to identify characteristic lung lesions. In severe cases or when dissemination is suspected, a biopsy may be necessary for confirmation.
The rising prevalence of inhaling airborne fungal spores due to disturbances in the soil caused by factors like dust storms and construction activities is primarily driving the coccidioidomycosis market. In addition to this, the escalating incidence of somatic mutations in the GNAQ gene, leading to overgrowth of the fungus in certain regions of the body, particularly the respiratory system, is a crucial factor fueling the market growth. Furthermore, the increasing utilization of effective antifungal medications, such as azoles, polyenes, echinocandins, etc., to manage the condition and prevent complications is creating a positive outlook for the market. Apart from this, the widespread adoption of preventive measures, including wearing masks and avoiding high-risk areas, has also contributed to the market's expansion. Additionally, the rising popularity of early diagnosis through serological tests and chest X-rays, enabling prompt treatment and reducing disease progression, is acting as another significant growth-inducing factor. Moreover, the emerging trend of adopting combination therapy, involving a few different types of antifungal agents in severe cases, is further augmenting the market growth. Additionally, the growing research and development efforts towards launching a therapeutic vaccine aimed at providing long-term immunity and prevention against the disease are expected to drive the coccidioidomycosis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the coccidioidomycosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for coccidioidomycosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the coccidioidomycosis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the coccidioidomycosis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the coccidioidomycosis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current coccidioidomycosis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the coccidioidomycosis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the coccidioidomycosis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the coccidioidomycosis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of coccidioidomycosis across the seven major markets?
What is the number of prevalent cases (2018-2034) of coccidioidomycosis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of coccidioidomycosis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with coccidioidomycosis across the seven major markets?
What is the size of the coccidioidomycosis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of coccidioidomycosis?
What will be the growth rate of patients across the seven major markets?
Coccidioidomycosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for coccidioidomycosis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the coccidioidomycosis market?
What are the key regulatory events related to the coccidioidomycosis market?
What is the structure of clinical trial landscape by status related to the coccidioidomycosis market?
What is the structure of clinical trial landscape by phase related to the coccidioidomycosis market?
What is the structure of clinical trial landscape by route of administration related to the coccidioidomycosis market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 COCCIDIOIDOMYCOSIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 COCCIDIOIDOMYCOSIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 COCCIDIOIDOMYCOSIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 COCCIDIOIDOMYCOSIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 COCCIDIOIDOMYCOSIS - UNMET NEEDS
10 COCCIDIOIDOMYCOSIS - KEY ENDPOINTS OF TREATMENT
11 COCCIDIOIDOMYCOSIS - MARKETED PRODUCTS
11.1 List of Coccidioidomycosis Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 COCCIDIOIDOMYCOSIS - PIPELINE DRUGS
12.1 List of Coccidioidomycosis Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. COCCIDIOIDOMYCOSIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. COCCIDIOIDOMYCOSIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 COCCIDIOIDOMYCOSIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Coccidioidomycosis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Coccidioidomycosis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Coccidioidomycosis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Coccidioidomycosis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Coccidioidomycosis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Coccidioidomycosis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Coccidioidomycosis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Coccidioidomycosis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Coccidioidomycosis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Coccidioidomycosis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Coccidioidomycosis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Coccidioidomycosis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Coccidioidomycosis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Coccidioidomycosis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Coccidioidomycosis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Coccidioidomycosis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Coccidioidomycosis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Coccidioidomycosis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Coccidioidomycosis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Coccidioidomycosis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Coccidioidomycosis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Coccidioidomycosis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Coccidioidomycosis - Access and Reimbursement Overview
16 COCCIDIOIDOMYCOSIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 COCCIDIOIDOMYCOSIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 COCCIDIOIDOMYCOSIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 COCCIDIOIDOMYCOSIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 COCCIDIOIDOMYCOSIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 COCCIDIOIDOMYCOSIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 COCCIDIOIDOMYCOSIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 COCCIDIOIDOMYCOSIS - UNMET NEEDS
10 COCCIDIOIDOMYCOSIS - KEY ENDPOINTS OF TREATMENT
11 COCCIDIOIDOMYCOSIS - MARKETED PRODUCTS
11.1 List of Coccidioidomycosis Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 COCCIDIOIDOMYCOSIS - PIPELINE DRUGS
12.1 List of Coccidioidomycosis Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. COCCIDIOIDOMYCOSIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. COCCIDIOIDOMYCOSIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 COCCIDIOIDOMYCOSIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Coccidioidomycosis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Coccidioidomycosis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Coccidioidomycosis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Coccidioidomycosis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Coccidioidomycosis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Coccidioidomycosis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Coccidioidomycosis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Coccidioidomycosis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Coccidioidomycosis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Coccidioidomycosis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Coccidioidomycosis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Coccidioidomycosis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Coccidioidomycosis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Coccidioidomycosis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Coccidioidomycosis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Coccidioidomycosis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Coccidioidomycosis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Coccidioidomycosis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Coccidioidomycosis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Coccidioidomycosis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Coccidioidomycosis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Coccidioidomycosis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Coccidioidomycosis - Access and Reimbursement Overview
16 COCCIDIOIDOMYCOSIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 COCCIDIOIDOMYCOSIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 COCCIDIOIDOMYCOSIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
